Sleep Dysfunction in Huntington's Disease: impacts of current medications and prospects for treatment

Owen NE¹, Barker RA¹,², Voysey ZJ¹.

¹Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK.

²Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0PY, UK.

Corresponding Author:

Natalia Owen¹

Address: Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, CB2 0PY, UK.

Email address: neo25@cam.ac.uk

Telephone number: +12535613137
Abstract

Sleep dysfunction is highly prevalent in Huntington’s disease (HD). Increasing evidence suggests that such dysfunction not only impairs quality of life and exacerbates symptoms but may even accelerate the underlying disease process. Despite this, current HD treatment approaches neither consider the impact of commonly used medications on sleep, nor directly tackle sleep dysfunction.

In this review, we discuss approaches to these two areas, evaluating not only literature from clinical studies in HD, but also that from parallel neurodegenerative conditions and preclinical models of HD. We conclude by summarizing a hierarchical framework of current medications with regard to their impact on sleep, and by outlining key emerging sleep therapies.

Key Words: Huntington’s disease, Sleep, Neurodegeneration, Insomnia, Somnolence
Introduction

Huntington’s disease (HD) is an autosomal-dominant hereditary neurodegenerative condition, characterized by a triad of motor, cognitive and psychiatric features, resulting from a polyglutamine expansion mutation in exon 1 of the huntingtin gene. As there is currently no treatment that slows or halts the progression of the disease, contemporary treatment approaches are symptomatic.

Sleep dysfunction represents one such highly prevalent symptom. On a clinical level, this manifests most commonly as onset and maintenance insomnia, as well as abnormal motor activity during sleep and nocturnal awakenings [1-5]. On a polysomnographic level, such dysfunction results in sleep structure fragmentation [6-7] (Figure 1) and loss of slow wave sleep (SWS) and rapid eye movement (REM) sleep. Notably, these sleep deficits have been identified during the premanifest stage far from disease onset [2, 7-8], arguing against the idea that sleep dysfunction occurs predominantly as a result of medication or psychiatric symptoms of HD such as depression or anxiety.

Importantly, growing evidence suggests a damaging feedforward cycle between such sleep dysfunction and neurodegeneration. Sleep dysfunction is recognized to exacerbate a range of cognitive symptoms, including deficits in executive function, memory consolidation, attention and processing speed, as well as affective features such as impulsivity and emotional liability [9-13]. Sleep disruption may also directly affect neurodegenerative processes by inducing neuroinflammation [14] or impairing SWS-dependent glymphatic clearance of neurotoxic waste [15-16]. Consequently, sleep deprivation is associated with an increase in neurotoxic proteins such as beta-amyloid and tau; known contributors of neurodegeneration [16-17]. This is also relevant to HD given the recent links to tau and disease progression [18].
Given this feedforward relationship, addressing sleep pathology in HD potentially offers a treatment approach that not only could alleviate motor, cognitive, and psychiatric symptoms but may also modify disease progression. Consistent with this, sleep interventions in preclinical models of HD have enhanced both behavioral and survival outcomes [19-24]. Thus, there exists a clear need for i) greater consideration of how commonly prescribed HD medications impact sleep in this condition, and ii) identification of the best approaches for treating such sleep dysfunction. This review aims to discuss these two areas (Table 1).

**Current Medications: Impact on Sleep**

**Tetrabenazine/Deutetrabenazine**

Tetrabenazine and deutetrabenazine are the most commonly used antidopaminergic agents to treat chorea associated with HD. Both are vesicular monoamine transporter 2 (VMAT2) inhibitors that block the loading of dopamine into presynaptic vesicles, thereby reducing dopamine release and, consequently, lessening chorea. Currently, tetrabenazine and deutetrabenazine are the only agents approved by the US Food and Drug Administration for the pharmacological treatment of the chorea in HD.

Multiple studies of tetrabenazine (TBZ) in hyperkinetic movement disorders demonstrate that it elicits insomnia in 5-33% of patients [25-30]. Moreover, studies have shown that TBZ also carries a risk of causing depression in 8-37% of patients [26-29, 31]. Given the potential for depression to provoke or exacerbate insomnia [32], this further adds to the risk of this agent mediating sleep disruption in HD. There is also evidence that TBZ may influence daytime alertness: multiple studies have noted drowsiness or somnolence as occurring in 25-39% of patients treated with tetrabenazine [25-26, 28, 30], and in a 12-week randomized controlled trial conducted by the Huntington Study Group, the treatment group receiving tetrabenazine
experienced a significant dose dependent increase in drowsiness and insomnia compared to the control group [33].

In contrast, studies of deutetrabenazine in hyperkinetic movement disorders have either shown no, rare, or insignificant levels of insomnia as an adverse event [34], as well as low rates of depression [34-36]. A randomized clinical trial of deutetrabenazine conducted by the Huntington Study Group cited somnolence as reported by 11% of patients in the treatment group [34], but there was no significant difference in Epworth Sleepiness Scale (ESS) scores. Other studies also report somnolence as the most common adverse event in patients treated with deutetrabenazine, but at lower rates (5-15%) than those observed for tetrabenazine [35-36, 37]. Moreover, a direct head-to-head study found a significantly lower risk of adverse events, including depression, drowsiness/somnolence, and insomnia, associated with deutetrabenazine compared to tetrabenazine [38].

**Antipsychotics**

Dopamine receptor antagonists, such as typical and atypical antipsychotics, are used to treat both psychiatric symptoms and chorea in HD patients.

Unlike VMAT2 inhibitors, antipsychotics exhibit a relatively favorable sleep profile. Olanzapine has been shown to improve behavioral symptoms and chorea in HD patients with no significant adverse effects related to sleep disturbance [39-41]. Polysomnographic (PSG) studies in healthy individuals, and in those with depression or schizophrenia, have shown increases in total sleep time, sleep efficiency and proportion of slow wave sleep (SWS) in response to atypical antipsychotic therapy [42-47]. These studies all investigated olanzapine, however acute administration with other atypical antipsychotics, such as risperidone [48-49] and quetiapine [50-51], are also associated with increases in total sleep time, percentage of SWS and improved
sleep efficiency in healthy populations as well as in subjects with depression. Such an effect on
SWS is particularly notable, given the specific loss of SWS in HD, and the role of SWS in
glymphatic clearance of neurotoxic waste and memory consolidation [15, 52-54]. Though there
are no PSG studies on the effects of antipsychotics specifically in HD, several studies using
clinical outcome measures have shown improvements in insomnia [55-56]. Typical
antipsychotics, such as haloperidol, have been associated with sedation and somnolence side
effects, while other studies have demonstrated that atypical antipsychotics tend to have less of a
sedative effect without compromising efficacy [57].

Thus, atypical antipsychotics represent a comparatively sleep-benign option in the
treatment of chorea in HD. Nonetheless, this benefit needs to be offset against data from the
broader dementia literature that suggest antipsychotics carry an increased risk of hip fracture,
cognitive decline, cerebrovascular accident, and death [58-61], which may also be the case for
HD [62].

**Antidepressants**

Due to the bidirectional relationship between sleep loss and depression [63],
pharmacological treatment of depression bears potential to improve sleep quality. Indeed, sleep
and depression have been notably tightly bound in HD, with sleep disturbances occurring more
prevalently in HD patients with coexisting depression [64-65].

However, on a pharmacological level, both SSRIs and SNRIs have been found to carry a
risk of eliciting insomnia, with clinical trials showing treatment-emergent insomnia in 17% of
patients treated with SSRIs compared to 9% in the placebo group and in 13% of patients treated
with SNRIs compared to 7% on placebo [66]. Moreover, regarding sleep architecture, both
SSRIs and SNRIs have been found to reduce sleep continuity and REM sleep as well as increase
REM latency [67]. Such adverse events are greatest during the first weeks of treatment but may persist.

Given this sleep-disrupting effect observed with SSRIs and SNRIs, sedating antidepressants, such as mirtazapine, amitriptyline, trazodone and doxepin, are a logical consideration. Mirtazapine, in particular, has been shown to improve sleep continuity and SWS via 5HT2 receptor antagonism in both healthy individuals and those with depression [68-73]. Increases in total sleep time and SWS have similarly been observed in studies of trazodone as a treatment for primary insomnia and co-occurring depression and insomnia as well as in healthy individuals [74-75]. Doxepin has also been shown to increase total sleep time and overall sleep efficiency in young, middle-aged, and elderly primary insomnia patients [76-78].

Nonetheless, a randomized controlled trial of mirtazapine in Alzheimer’s disease found no significant benefit to sleep outcomes [79], and the majority of sedating antidepressants have been found to carry a risk of significant daytime somnolence and cognitive impairment, with consequent adverse outcomes [58, 75, 80]. The average prevalence of somnolence from the US Food and Drug Administration study register was 54% in patients treated with mirtazapine compared to 18% in placebo-treated patients and 46% in patients treated with trazodone compared to 19% in placebo. This is compared to reports of somnolence in only 16% of SSRI-treated patients and 8% in the placebo arm and 10% of SNRI-treated patients with 5% in the placebo group [66].

Benzodiazepines and Z-drugs

Benzodiazepines and Z-drugs (e.g., zopiclone, zolpidem, and zaleplon) both act as GABA agonists. Such agents are commonly prescribed to address sleep symptoms in HD
patients and the general population, due to their known ability to reduce sleep latency and improve sleep continuity.

Studies in preclinical models of HD have shown cognitive benefits through the pharmacological normalization of sleep-wake cycles with a benzodiazepine [19]. However, this is unlikely to translate to clinical populations: both benzodiazepines and Z-drugs carry risks of tolerance, dependence, and withdrawal [81] as well as impairment of attention, psychomotor speed, and memory consolidation [82-87]. Additionally, reductions of REM and SWS have been observed in both benzodiazepine and Z-drug studies of healthy young, adult, and elderly populations [88-91]. Studies in healthy elderly populations and in Alzheimer’s disease have shown worse outcomes with benzodiazepine use [92-94]. Given these outcomes and the risk of side effects, benzodiazepines and Z-drugs are not recommended as pharmacological agents in the treatment of sleep dysfunction in HD.

Other agents

Lamotrigine

Lamotrigine, a mood stabilizer that acts by reducing the release of glutamate, may be used to address issues of mood lability and motor symptoms in HD patients [95-96]. There has as yet, been no direct study of the influence of lamotrigine on sleep in HD. Symptomatic studies in epilepsy have suggested lamotrigine may cause insomnia in 6-19% of patients [97-98]. PSG studies investigating lamotrigine in the treatment of epilepsy have been inconsistent, with some reporting loss of SWS [99] while others report a significant gain in REM sleep [100].

Amantadine

Amantadine has been used to treat chorea and balance impairment in HD. Though its mechanism of action is not fully known, amantadine is thought to work at the level of the
striatum on dopamine via NMDA receptors. In a blinded, randomized controlled trial of 24 HD patients, 25% experienced subjective insomnia during the treatment phase, compared to 12.5% when on placebo [101]. However, rates of insomnia and somnolence were insignificant or nonexistent in other randomized controlled trials of amantadine in both Huntington’s and Parkinson’s disease patients [102-103].

Riluzole

Riluzole, a benzothiazole that reduces glutamate release, has been reported to improve chorea associated with HD without significant sleep-related adverse events in one study [104]. A three-year randomized controlled study of riluzole in HD found lower insomnia frequency in the treatment group compared to placebo [105].

Prospects for treatment

To date, there has been no large-scale sleep intervention study in a clinical HD population. However, positive results from preclinical studies, as well as clinical studies in other neurodegenerative conditions, merit consideration in guiding prospects for treatment.

Treating abnormal motor activity in sleep

Several studies report finding an increased prevalence of a periodic limb movement disorder (PLMD) in HD [1-2]. Where suspected, rationalizing any tricyclic or SSRI antidepressant use may therefore be warranted, alongside consideration of gabapentin or clonazepam, taking into account the caveats discussed above. However, there is considerable controversy as to the nature of abnormal nocturnal motor activity in HD, with several studies instead identifying nocturnal motor activity as chorea, repetitive ballistic movements and atypical high amplitude repositioning movements during arousals to wakefulness [3-5]. As such,
where a patient or their bed partner reports abnormal nocturnal motor activity which does not respond to olanzapine, referral for dedicated video polysomnography may be worthwhile.

Cognitive Behavioral Therapy for Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) employs a combination of behavioral measures to improve sleep quality, including stimulus control, sleep restriction, sleep hygiene, cognitive therapy, and relaxation techniques. As an example, sleep hygiene involves adherence to regular sleep/wake times and optimization of bedroom temperature, among other factors.

Strong evidence exists for the efficacy of CBT-I and sleep hygiene behavioral measures in improving sleep quality in healthy populations [106]. A randomized controlled trial in older adults with chronic primary insomnia found greater improvements in sleep efficiency and duration of SWS associated with CBT-I compared to zopiclone [107]. Supportive evidence also exists for improved sleep efficiency in mixed dementia populations and in patients with mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease [108-115].

Of note, CBT-I-like behavioral interventions in preclinical models of HD have been beneficial, demonstrating cognitive improvements [51]. Moreover, though limited, a pilot study of CBT-I in premanifest HD patients along with exercise (aerobic and resistance training) and social measures (social events and group intervention sessions) showed gains in REM sleep [116].

However, several elements of CBT-I are clearly impractical in advanced dementia, and attrition rates have been reported to be as high as 40% in community studies [117]. Thus, the efficacy and feasibility of long-term CBT-I to treat sleep dysfunction in HD remains ambiguous and is likely to be of most use in addressing sleep dysfunction present in the premanifest or prodromal phase of the condition.
Bright Light Therapy

Bright light therapy is known to modulate both circadian rhythm and sleep quality through its influence on melatonin secretion.

Notably, preclinical models of HD have suggested a possible benefit of bright light therapy to motor performance and survival outcomes [21-22], raising hopes of translation to clinical HD populations. Some clinical studies have found evidence of benefits in dementia cohorts, reporting increased total sleep time and reduced wake time after sleep onset [118-120]. However, many of these studies are marred by a likely placebo effect [121-122]. Overall, meta-analyses have not suggested high efficacy in dementia populations [123-126]. As with CBT-I, there are also clear practical considerations limiting use of bright light therapy in dementia and other psychiatric populations, as non-adherence to the treatment protocol is typically high [127], as was also evident in our own pilot study of bright light therapy in HD (A. Lazar and R. A. Barker, 2023, personal communication).

Melatonin

Allied to bright light therapy, direct exogenous melatonin has been widely studied as an alternative pharmacological treatment for sleep dysfunction. It is of particular relevance to Huntington’s disease, since a diminished melatonin secretion profile has been recognized as part of the condition [128-129].

However, the evidence for the beneficial effect of melatonin on sleep dysfunction in neurodegenerative populations remains inconclusive. Multiple studies in both Alzheimer’s and Parkinson’s disease have failed to consistently show that melatonin has a beneficial effect on sleep quality. Evidence from a randomized controlled trial in Alzheimer’s disease patients [130], and a blinded cross-over study in individuals with mild cognitive impairment [131] suggested
improvement in sleep quality with exogenous melatonin. However, in contrast, three other randomized controlled trials in Alzheimer’s disease have shown no benefit [132-134]. Similarly, no clinically significant benefits have been reported from placebo-controlled trials in Parkinson’s disease [135-136].

Though no studies to date have directly investigated the use of melatonin as a pharmacological intervention to treat sleep abnormalities in Huntington’s disease, an ongoing pilot blinded clinical trial is examining the effects of melatonin as a dietary supplement in improving sleep quality in Huntington’s disease patients (https://clinicaltrials.gov/ct2/show/NCT04421339).

**Sodium Oxybate**

Typically used to treat narcolepsy, sodium oxybate is thought to act through GABA receptor activity to reduce cataplexy and daytime somnolence. A number of studies have demonstrated parallel beneficial effects on slow wave sleep, and an ability to counter the cognitive impact of sleep loss in healthy adults [137]. Two studies in Parkinson’s disease have supported the efficacy of sodium oxybate in improving both subjective sleep quality and objective slow wave sleep duration [138-139]. Moreover, animal models of neurodegeneration investigating sodium oxybate observed a protective action against toxic proteinopathies [140]. Such promising results position sodium oxybate as an important potential pharmacological treatment for sleep dysfunction in neurodegenerative disorders. However, sodium oxybate has not yet been directly trialed as a pharmacological agent in the treatment of Alzheimer’s or Huntington’s disease, and its use is not straightforward due to its classification as a controlled substance.

**Acoustic Stimulation**
There is robust evidence supporting the ability of pulsed acoustic stimulation during sleep to augment slow wave sleep and enhance memory consolidation [141-142]. While it may seem improbable that pulses of sound alone could have such an effect, this has been demonstrated in numerous blinded studies and is thought to be mediated by the unique interaction between the nonlemniscal acoustic pathway and diffuse thalamocortical projections during sleep, wherein acoustic stimuli evoke widespread synchronous slow oscillations that underpin slow wave sleep.

Such benefits of acoustic stimulation to slow wave sleep and cognition have been demonstrated in healthy populations including elderly cohorts [143-149]. To date, there has only been one study in a neurodegenerative cohort, that of mild cognitive impairment, in which an increase in slow wave activity was observed and associated with improving memory performance [150].

Acoustic stimulation, for example delivered by headset devices such as the Philips Deep Sleep Headband, therefore represents a further novel therapy for HD, with its non-pharmacological and non-invasive method of delivery, practicality in the home, and low cost all making it an attractive option. However, the long-term effects of acoustic stimulation currently remain unknown, and no clinical trial has yet been undertaken in an HD cohort.

**Orexin Antagonists**

Orexin antagonists, such as suvorexant and lemborexant, represent a further emerging area of sleep therapies. They are designed to treat insomnia through their inhibition of orexin, a neuropeptide that acts as a key alerting agent in the regulation of the sleep-wake cycle.

Several randomized clinical trials offer support for the use of orexin antagonists in both healthy older adults and in Alzheimer’s disease patients to treat insomnia, demonstrating increases in total sleep time as well as a reduction in wake time after sleep onset [151-154]. One
study comparing an orexin antagonist and zolpidem in young healthy adults found less cognitive and executive impairments under the orexin antagonist [155]. Moreover, orexin antagonists do not appear to have any detrimental effect on sleep architecture and seem, overall, to be well tolerated [151, 153, 156]. Though no clinical trials have yet been conducted in HD, importantly, preclinical data has supported the potential benefit of orexin antagonists in addressing sleep dysfunction [24].

**Conclusion**

Addressing sleep dysfunction in Huntington’s disease bears potential to improve clinical outcomes and overall quality of life for patients and their families. There is a pressing need for greater consideration of the impact on sleep when managing patients with HD, including the possible detrimental effects of drugs used to treat other aspects of HD (e.g., chorea) on sleep.

Of commonly used medications, current evidence suggests that atypical antipsychotics and sedating antidepressants carry the most favorable profile with respect to supporting improved and healthy sleep. However, in both cases this needs to be offset against their risk of eliciting daytime somnolence and consequent cognitive impairment, falls, and other adverse events. In terms of VMAT inhibitors, deutetrabenazine appears to carry a more sleep-benign profile when compared against tetrabenazine. Limited evidence exists with respect to the effect of lamotrigine, amantadine and riluzole on sleep profiles, but so far the data suggest that only riluzole may have benefits for sleep. Benzodiazepines and Z-drugs are not recommended, both due to their detrimental effect on sleep architecture and associated adverse outcomes.

With respect to direct sleep therapies, clinical trials in parallel neurodegenerative conditions have, to date, largely failed to demonstrate benefit from bright light therapy or exogenous melatonin. Nevertheless, the results of a pilot trial of melatonin in a Huntington’s
disease cohort are awaited. Supportive evidence exists for the benefit of CBT-I, both from preclinical models of HD and clinical studies in other neurodegenerative conditions. Nonetheless, practical considerations are clearly paramount in such an intervention in an HD cohort, such that it is likely that CBT-I would be most efficacious in premanifest or prodromal HD patients. By contrast, sodium oxybate, orexin antagonists and slow wave sleep augmentation by acoustic stimulation are all emerging as promisingly efficacious and practical new sleep therapies, and clinical trials of these agents in HD should be undertaken.

Acknowledgements

Zanna Voysey is funded by an Association of British Neurologists/Guarantors of Brain Clinical Research Fellowship. This research was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Conflict of Interest

The authors have no conflict of interest to report.

References


Nocturnal agitation in Huntington disease is caused by arousal-related abnormal movements rather than by rapid eye movement sleep behavior disorder. Sleep medicine. 2015 Jun 1;16(6):754-9.


Beattie L, Kyle SD, Espie CA, Biello SM. Social interactions, emotion and sleep: A systematic review and research agenda. Sleep medicine reviews. 2015 Dec 1;24:83-100.


[136] Medeiros CA, Carvalhede de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, Sales de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in


Table 1. Sleep-Related Effects of Treatments Relevant to HD

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Populations Trialed</th>
<th>Mechanism of Action</th>
<th>Reported Sleep Benefits</th>
<th>Reported Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacological</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetrabenazine</td>
<td>HD, hyperkinetic movement disorders</td>
<td>VMAT2 inhibitor</td>
<td>Unknown</td>
<td>Insomnia, depression, daytime somnolence</td>
</tr>
<tr>
<td>Deutetrabenazine</td>
<td>HD, hyperkinetic movement disorders</td>
<td>VMAT2 inhibitor</td>
<td>Unknown</td>
<td>Daytime somnolence (lower rates than with tetrabenazine)</td>
</tr>
<tr>
<td>Atypical Antipsychotics</td>
<td>HD, depression, schizophrenia, healthy</td>
<td>Serotonin-dopamine (D2) antagonist</td>
<td>↑ TST</td>
<td>Cognitive impairment, hip fracture, CVA, death</td>
</tr>
<tr>
<td>Olanzapine</td>
<td></td>
<td></td>
<td>↑ SE</td>
<td></td>
</tr>
<tr>
<td>Risperidone</td>
<td></td>
<td></td>
<td>↑ SWS proportion</td>
<td></td>
</tr>
<tr>
<td>Quetiapine</td>
<td></td>
<td></td>
<td>↓ Insomnia</td>
<td></td>
</tr>
<tr>
<td><strong>SSRIs/SNRIs</strong></td>
<td>Depression</td>
<td>Selective serotonin/norepinephrine reuptake inhibitor</td>
<td>Unknown</td>
<td>Insomnia, ↓ sleep continuity, ↓ REM sleep, ↑ REM latency</td>
</tr>
<tr>
<td><strong>Sedating Antidepressants</strong></td>
<td>Primary insomnia, depression, healthy</td>
<td>Antagonism at 5HT2 receptor</td>
<td>↑ TST</td>
<td>Daytime somnolence, cognitive impairment</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td></td>
<td></td>
<td>↑ SE</td>
<td></td>
</tr>
<tr>
<td>Trazodone</td>
<td></td>
<td></td>
<td>↑ SWS proportion</td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Benzodiazepines/Z-drugs</strong></td>
<td>HD (preclinical), AD, healthy</td>
<td>GABA agonist</td>
<td>↓ sleep latency</td>
<td>↓ REM, ↓ SWS, tolerence, dependance,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ sleep continuity</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Disorder</td>
<td>Mechanism</td>
<td>Effect</td>
<td>Possible Side Effects</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Epilepsy</td>
<td>Glutamate-release inhibitor</td>
<td>Inconclusive</td>
<td>Inconclusive (potential ↑ REM) and ↓ SWS</td>
</tr>
<tr>
<td>Amantadine</td>
<td>HD, PD</td>
<td>Likely NMDA receptors</td>
<td>Unknown</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Riluzole</td>
<td>HD</td>
<td>Glutamate antagonist</td>
<td>↓ insomnia (limited evidence)</td>
<td>Insignificant</td>
</tr>
<tr>
<td>Exogenous Melatonin</td>
<td>AD, PD, MCI</td>
<td>Circadian rhythm</td>
<td>Inconclusive</td>
<td>None</td>
</tr>
<tr>
<td>Sodium Oxybate</td>
<td>PD, healthy</td>
<td>GABA receptor agonist</td>
<td>↑ SWS duration</td>
<td>None</td>
</tr>
<tr>
<td>Orexin Antagonists</td>
<td>AD, healthy</td>
<td>Orexin inhibitors</td>
<td>↑ TST</td>
<td>None</td>
</tr>
<tr>
<td>Orexin Antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Suvorexant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lemborexant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonpharmacological</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBT-I</td>
<td>HD (preclinical and premanifest), mixed dementia, MCI, AD, PD, healthy</td>
<td>Behavioral measures</td>
<td>↑ SE</td>
<td>None</td>
</tr>
<tr>
<td>Bright Light Therapy</td>
<td>HD (preclinical), dementia</td>
<td>Circadian rhythm</td>
<td>Inconclusive</td>
<td>None</td>
</tr>
<tr>
<td>Acoustic Stimulation</td>
<td>MCI, healthy</td>
<td>Nonlemniscal acoustic pathway and thalamocortical projections</td>
<td>↑ SWS</td>
<td>Long-term effects unknown</td>
</tr>
</tbody>
</table>

Figure 1. Polysomnography exhibiting insomnia and sleep architecture fragmentation in HD, sourced from ongoing research in our group (unpublished). Figures depict hypnograms from two control examples and two early manifest HD patient examples, between 22:00 and 07:00. U: un-scored. W: wake. R: rapid eye movement (red). N1: stage 1 sleep, N2: stage 2 sleep, N3: slow wave sleep.